These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27168098)

  • 21. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.
    Hughes AR; Spreen WR; Mosteller M; Warren LL; Lai EH; Brothers CH; Cox C; Nelsen AJ; Hughes S; Thorborn DE; Stancil B; Hetherington SV; Burns DK; Roses AD
    Pharmacogenomics J; 2008 Dec; 8(6):365-74. PubMed ID: 18332899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HLA pharmacogenetic markers of drug hypersensitivity from the perspective of the populations of the Greater Middle East.
    Masmoudi HC; Afify N; Alnaqbi H; Alhalwachi Z; Tay GK; Alsafar H
    Pharmacogenomics; 2022 Aug; 23(12):695-708. PubMed ID: 35971864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.
    Rodríguez-Nóvoa S; García-Gascó P; Blanco F; González-Pardo G; Castellares C; Moreno V; Jiménez-Nácher I; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1374-6. PubMed ID: 18184080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA alleles and drug hypersensitivity reactions.
    Profaizer T; Eckels D
    Int J Immunogenet; 2012 Apr; 39(2):99-105. PubMed ID: 22136512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetic determinants of immediate and delayed reactions of drug hypersensitivity.
    Guéant JL; Guéant-Rodriguez RM; Gastin IA; Cornejo-García JA; Viola M; Barbaud A; Mertes PM; Blanca M; Romano A
    Curr Pharm Des; 2008; 14(27):2770-7. PubMed ID: 18991696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
    Berka N; Gill JM; Liacini A; O'Bryan T; Khan FM
    Hum Immunol; 2012 Feb; 73(2):164-7. PubMed ID: 22197535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful translation of pharmacogenetics into the clinic: the abacavir example.
    Phillips E; Mallal S
    Mol Diagn Ther; 2009; 13(1):1-9. PubMed ID: 19351209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacogenetic contribution to individualized treatment. Severe adverse effects can be avoided].
    Eliasson E
    Lakartidningen; 2008 May 28-Jun 3; 105(22):1644-5. PubMed ID: 18590003
    [No Abstract]   [Full Text] [Related]  

  • 29. Abacavir hypersensitivity reaction predicted by genetic test.
    AIDS Treat News; 2004 Mar; (399):6. PubMed ID: 15199868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
    Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
    Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genotyping for severe drug hypersensitivity.
    Karlin E; Phillips E
    Curr Allergy Asthma Rep; 2014 Mar; 14(3):418. PubMed ID: 24429903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenomics of antimicrobial agents.
    Aung AK; Haas DW; Hulgan T; Phillips EJ
    Pharmacogenomics; 2014; 15(15):1903-30. PubMed ID: 25495412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos.
    Sanchez-Giron F; Villegas-Torres B; Jaramillo-Villafuerte K; Silva-Zolezzi I; Fernandez-Lopez JC; Jimenez-Sanchez G; Carnevale A
    Pharmacogenomics; 2011 Jun; 12(6):809-14. PubMed ID: 21510768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.
    Hughes DA; Vilar FJ; Ward CC; Alfirevic A; Park BK; Pirmohamed M
    Pharmacogenetics; 2004 Jun; 14(6):335-42. PubMed ID: 15247625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HLA-B*5701 screening for hypersensitivity to abacavir.
    Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
    N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future.
    Alfirevic A; Pirmohamed M
    Pharmacogenomics; 2010 Apr; 11(4):497-9. PubMed ID: 20350129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV.
    Quiros-Roldan E; Gardini G; Properzi M; Ferraresi A; Carella G; Marchi A; Malagoli A; Focà E; Castelli F
    Pharmacogenet Genomics; 2020 Oct; 30(8):167-174. PubMed ID: 32453265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions.
    Ingelman-Sundberg M
    N Engl J Med; 2008 Feb; 358(6):637-9. PubMed ID: 18256400
    [No Abstract]   [Full Text] [Related]  

  • 39. [Importance of HLA in Determining Individual Differences in the Onset of Adverse Drug Reactions].
    Aoki S
    Yakugaku Zasshi; 2021; 141(8):1001-1007. PubMed ID: 34334545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
    Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
    Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.